COVID-19 antibody
/ Roche, A*Star
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
November 27, 2023
SCAPE-HIV: SARS-CoV-2 (COVID-19) Antibody PrevalencE in an Adult London HIV Cohort
(clinicaltrials.gov)
- P=N/A | N=615 | Completed | Sponsor: Royal Free Hospital NHS Foundation Trust | Recruiting ➔ Completed | N=1500 ➔ 615 | Trial completion date: Apr 2022 ➔ Jun 2023
Enrollment change • Trial completion • Trial completion date • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
December 21, 2022
"U.S. FDA approves Roche's COVID-19 antibody https://t.co/fOZZzZskt8"
(@Reuters)
FDA event • Infectious Disease • Novel Coronavirus Disease
November 21, 2021
"European regulators recommend #COVID-19 antibody drugs @Regeneron @Roche @CelltrionDream https://t.co/wbH7JiUOyC"
(@ChEnected)
Infectious Disease • Novel Coronavirus Disease
1 to 3
Of
3
Go to page
1